Methods of Making and Using Stable Pharmaceutical Compositions Comprising Ketotifen and Naphazoline
Stable compositions comprising ketotifen or a ketotifen salt and methods of preparing such compositions are provided. The pH of the compositions remains at less than about 5 during storage. The methods comprise preparing pharmaceutical compositions comprising ketotifen or a ketotifen salt, and adjusting their pH to less than 5, thus slowing the changes of the active ingredients.
1 . A method of preparing a stabilized ophthalmic composition, the method comprising:
(a) preparing an aqueous solution consisting essentially of: (1) ketotifen or a ketotifen salt in a concentration from about 0.001% to about 0.2% (w/v); (2) naphazoline or a naphazoline salt in a concentration from about 0.001% to about 0.2% (w/v); (3) glycerol; (4) a preservative; and (5) water; and
(b) adjusting a pH value of the aqueous solution to less than or equal to about 5;
thereby providing said stabilized ophthalmic composition, wherein the pH value of the ophthalmic composition is maintainable between about 4.3 to about 4.8 when kept at 40° C. and 20% relative humidity for at least 10 days.
2 . The method of claim 1 , wherein said ketotifen or ketotifen salt is in a concentration from about 0.01% to about 0.05% (w/v), and said naphazoline or naphazoline salt is in a concentration from about 0.01% to about 0.1% (w/v).
3 . The method of claim 2 , wherein said adjusting a pH comprises adding an adjusting agent that consists essentially of a solution of fumaric acid and sodium fumarate, or a solution of dilute hydrochloric acid.
4 . The method of claim 2 , wherein the glycerol is present at a concentration such that the solution has an osmolality of from 200 to 700 mOsm/kg.
5 . The method of claim 2 , wherein the glycerol is present at a concentration such that the solution has an osmolality of from 400 to 600 mOsm/kg.
6 . The method of claim 2 , wherein glycerol is present at a concentration from about 1% to about 6% (w/v).
7 . The method of claim 2 , wherein no more than about 10% of the ketotifen or the ketotifen salt is degraded at 40° C. and 20% relative humidity for at least 10 days.
8 . The method of claim 2 , wherein no more than about 5% of the naphazoline or the naphazoline salt is degraded at 40° C. and 20% relative humidity for at least 10 days.
9 . The method of claim 2 , wherein less than 10% of the ketotifen or the ketotifen salt and less than 5% of the naphazoline or the naphazoline salt are degraded at 40° C. and 20% relative humidity for at least 10 days.
10 . A method of preparing a stabilized ophthalmic composition, the method comprising:
(a) preparing an aqueous solution consisting essentially of: (1) ketotifen or a ketotifen salt in a concentration of from about 0.001% to about 0.2% (w/v); (2) naphazoline or a naphazoline salt in a concentration of from about 0.001% to about 0.2% (w/v); (3) glycerol; (4) benzalkonium chloride; (5) water; and (6) a buffering agent; and
(b) adjusting a pH value of the aqueous solution to less than or equal to about 5;
thereby providing a stabilized ophthalmic composition wherein the pH value of the ophthalmic composition is maintainable between about 4.3 to about 4.8 when kept at 40° C. and 20% relative humidity for at least 10 days.
11 . The method of claim 10 , wherein said ketotifen or ketotifen salt is in a concentration from about 0.01% to about 0.05% (w/v); and said naphazoline or a naphazoline salt is in a concentration of from about 0.01% to about 0.1% (w/v).
12 . The method of claim 11 , wherein the buffering agent is present in a concentration such that an initial pH value of the aqueous solution decreases when kept at 40° C. and 20% relative humidity for at least 10 days.
13 . The method of claim 11 , wherein the buffering agent is citrate that is present in a concentration of about 0.002 M or less; or phosphate that is present at a concentration of 0.004 M or less.
14 . A method of preparing a stabilized ophthalmic composition, the method comprising:
(a) preparing a ophthalmic composition comprising: (1) ketotifen in a concentration of about 0.001% to about 0.2% (w/v); (2) naphazoline in a concentration of about 0.001% to about 0.2% (w/v); (3) glycerol in a concentration of about 2% to 6% (w/v); and (4) water; and
(b) adjusting the pH value of the ophthalmic composition;
thereby providing said stabilized ophthalmic composition such that the pH value of the ophthalmic composition is between about 4.3 and about 4.8 at 40° C. and 20% relative humidity for at least 10 days.
15 . The method of claim 14 , wherein the osmolality of the composition is from about 400 to about 600 mOsm/kg.
16 . The method of claim 15 , wherein the composition further comprises a citrate buffer at a concentration of about 0.002 M, or less or a phosphate buffer at a concentration of 0.004 M or less.
17 . A method of preparing a stabilized aqueous ketotifen salt composition, the method comprising:
(a) admixing an aqueous ketotifen salt composition with a pH adjusting agent to produce a mixture, the pH adjusting agent providing a pH of the aqueous ketotifen salt composition in a range from about 4.8 to less than 5, wherein the composition is essentially free of buffer agents; and
(b) allowing the pH of the aqueous ketotifen salt composition to adjust to between 4.3 to less than 4.8;
thereby providing a stabilized aqueous ketotifen salt such that no more than about 10% of the ketotifen salt is degraded at 40° C. and 20% relative humidity for at least 10 days.
18 . The method of claim 17 , wherein the pH adjusting agent consists essentially of dilute hydrochloric acid.
19 . The method of claim 18 , wherein the pH adjusting agent consists essentially of a mixture of fumaric acid and sodium fumarate.
20 . The method of claim 17 , wherein the ketotifen salt is ketotifen fumarate.
21 . The method of claim 20 , wherein the ketotifen fumarate is present in a concentration of from about 0.01% to about 0.05%.
22 . The method of claim 19 , further comprising adding an anti-redness agent to the mixture.
23 . The method of claim 22 , wherein the anti-redness agent is naphazoline or naphazoline hydrochloride.
24 . The method of claim 23 , wherein the naphazoline or naphazoline hydrochloride is present in a concentration of from about 0.01% to about 0.1%.
25 . The method of claim 17 , further comprising adding a nonionic tonicity agent to the mixture.
26 . The method of claim 25 , wherein the nonionic tonicity agent is present at a concentration such that the composition has an osmolality of from 200 to 700 mOsm/kg.
27 . The method of claim 25 , wherein the nonionic tonicity agent is present at a concentration such that the composition has an osmolality of from 400 to 600 mOsm/kg.
28 . The method of claim 25 , wherein the nonionic tonicity agent is glycerol.
29 . The method of claim 28 , wherein the glycerol is present in a concentration of about 2% to about 6%.
30 - 40 . (canceled)